Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patientsWilma Barcellini, Alberto Zanella, Bruno Fattizzo et al.|Blood|2014Cited by 371
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Sergio Amadori, Paolo de Fabritiis et al.|Blood|2019Cited by 215
Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centersWilma Barcellini, Agostino Cortelezzi, Anna Zaninoni et al.|American Journal of Hematology|2018Cited by 80